Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Lerebours

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Oncogene|January 7, 2023
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access programD Bello Roufai, A Gonçalves, T De La Motte Rouge, et al.
Oncogene|March 16, 2023
Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access programD Bello Roufai, A Gonçalves, T De La Motte Rouge, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2019
Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysisA R Ferreira, A Di Meglio, B Pistilli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2017
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumabJ-Y Pierga, F-C Bidard, A Autret, et al.
ESMO Open|January 20, 2026
Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancerF Lynce, C Valenza, S M Niman, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Oncogene|January 7, 2023
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access programD Bello Roufai, A Gonçalves, T De La Motte Rouge, et al.
Oncogene|March 16, 2023
Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access programD Bello Roufai, A Gonçalves, T De La Motte Rouge, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2019
Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysisA R Ferreira, A Di Meglio, B Pistilli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2017
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumabJ-Y Pierga, F-C Bidard, A Autret, et al.
ESMO Open|January 20, 2026
Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancerF Lynce, C Valenza, S M Niman, et al.
Pageof 5